Is Palantir Stock Overhyped?
At one point, it seemed like the software giant Palantir…
Sell
37
VCEL Quote, Financials, Valuation and Earnings
Last price:
$51.39
Seasonality move
:
-3.86%
Day range:
$49.27 - $51.67
52-week range:
$39.12 - $63.00
Dividend yield:
0%
P/E ratio:
285.33x
P/S ratio:
11.19x
P/B ratio:
8.79x
Volume:
607K
Avg. volume:
376K
1-year change:
7.45%
Market cap:
$2.6B
Revenue:
$237.2M
EPS (TTM):
$0.18
Analysts' Opinion
-
Consensus RatingVericel has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $65.75, Vericel has an estimated upside of 28.02% from its current price of $51.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing -16.82% downside risk from its current price of $51.36.
Fair Value
-
According to the consensus of 7 analysts, Vericel has 28.02% upside to fair value with a price target of $65.75 per share.
VCEL vs. S&P 500
-
Over the past 5 trading days, Vericel has underperformed the S&P 500 by -0.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vericel does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vericel has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Vericel reported revenues of $75.4M.
Earnings Growth
-
Vericel has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Vericel reported earnings per share of $0.38.
Enterprise value:
2.5B
EV / Invested capital:
8.39x
Price / LTM sales:
11.19x
EV / EBIT:
220.26x
EV / Revenue:
10.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-421.65x
Price / Operating cash flow:
1,104.80x
Enterprise value / EBITDA:
147.36x
Gross Profit (TTM):
$172.1M
Return On Assets:
2.71%
Net Income Margin (TTM):
4.37%
Return On Equity:
4.14%
Return On Invested Capital:
4.14%
Operating Margin:
24.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $164.4M | $197.5M | $237.2M | $65M | $75.4M | |
| Gross Profit | $109.8M | $135.6M | $172.1M | $48.5M | $58.5M | |
| Operating Income | -$17.1M | -$6.5M | $4.5M | $12.7M | $18.5M | |
| EBITDA | -$11.6M | $2.9M | $16.6M | $15.4M | $21.6M | |
| Diluted EPS | -$0.36 | -$0.08 | $0.18 | $0.27 | $0.38 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $123.6M | $158.5M | $186.9M | $205.6M | $212.8M | |
| Total Assets | $205.6M | $243.7M | $273M | $353.7M | $432.7M | |
| Current Liabilities | $22.5M | $26.1M | $37.5M | $45.7M | $50.3M | |
| Total Liabilities | $71.3M | $73.2M | $80.7M | $127.7M | $140.8M | |
| Total Equity | $134.3M | $170.5M | $192.3M | $226M | $292M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $17.7M | $35.3M | $58.2M | $10.1M | $22.2M | |
| Cash From Investing | -$36.2M | -$3.1M | -$79M | -$8.1M | -$14.7M | |
| Cash From Financing | $1M | $3.6M | $19.1M | $1.3M | $7.1M | |
| Free Cash Flow | $10.1M | $7.8M | -$5.8M | $2.3M | $8.5M | |
VCEL
Sector
Market Cap
$2.6B
$40.6M
Price % of 52-Week High
81.52%
46.01%
Dividend Yield
0%
0%
Shareholder Yield
-0.9%
-0.67%
1-Year Price Total Return
7.45%
-38.36%
Beta (5-Year)
1.785
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$53.46
200-day SMA
Buy
Level
$50.27
Bollinger Bands (100)
Sell
Level
46.9 - 59.88
Chaikin Money Flow
Sell
Level
-482M
20-day SMA
Sell
Level
$56.49
Relative Strength Index (RSI14)
Sell
Level
36.30
ADX Line
Sell
Level
19.43
Williams %R
Neutral
Level
-78.453
50-day SMA
Sell
Level
$57.16
MACD (12, 26)
Sell
Level
-1.74
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
731.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.429)
Buy
CA Score
(Annual)
Level (0.6273)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.5178)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Stock Forecast FAQ
In the current month, VCEL has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VCEL average analyst price target in the past 3 months is $65.75.
-
Where Will Vericel Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vericel share price will rise to $65.75 per share over the next 12 months.
-
What Do Analysts Say About Vericel?
Analysts are divided on their view about Vericel share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vericel is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is Vericel's Price Target?
The price target for Vericel over the next 1-year time period is forecast to be $65.75 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VCEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vericel is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VCEL?
You can purchase shares of Vericel via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vericel shares.
-
What Is The Vericel Share Price Today?
Vericel was last trading at $51.39 per share. This represents the most recent stock quote for Vericel. Yesterday, Vericel closed at $51.36 per share.
-
How To Buy Vericel Stock Online?
In order to purchase Vericel stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Texas Roadhouse a Buy, Sell or Hold?
Texas Roadhouse (NASDAQ:TXRH) is a popular chain of steakhouses with…
New Billion Dollar Contract Surprises GEO Analysts
While earnings appeared mixed at first glance, management’s comments on…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 42x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Alerts
Sell
10
PRAX alert for Mar 1
Praxis Precision Medicines [PRAX] is down 40.97% over the past day.
Sell
22
ACHC alert for Mar 1
Acadia Healthcare [ACHC] is down 25.48% over the past day.
Buy
75
GRRR alert for Mar 1
Gorilla Technology Group [GRRR] is up 21.83% over the past day.
